Published Date: 15 Apr 2024
One-third of patients experience responses when using adagrasib plus cetuximab, with a median overall survival of 15 points 9 months.
Read Full News1.
Many patients learn they could have cancer in the emergency department
2.
ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types
3.
EMA OKs Two Treatments for Small Cell Lung Cancer
4.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
5.
Temsirolimus Plus Chemotherapy Fails in Rare Childhood Cancer
1.
Modern Concepts in Oncology Across Clinical Settings
2.
Effective Management Strategies for Sickle Cell Crisis: Insights from Medical Experts
3.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
4.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
5.
Advanced Directions in Hematology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part II
2.
Clinical Insights in Oncology
3.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
5.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation